A Biosimilar to the reference product¹:

For prescribing information and adverse event reporting, click here

MYNZEPLI^®2mg (40mg/mL)

• Same adult indications^2,3

• Same dosing and a similar formulation^2,3

• Highly similar structure and function⁴

• Highly similar efficacy, safety and immunogenicity¹

• Pre-filled syringe designed for ease of use with appropriate
  handling and an acceptable safety profile confirmed in a
  clinical study⁵

• European manufacturing and supply chain assurance^6,7

• Manufactured using almost 100% renewable energy⁸

MYNZEPLI^® (aflibercept) is indicated for the treatment of adults with neovascular (wet) age-related macular degeneration (wAMD),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),visual impairment due to diabetic macular oedema (DME),visual impairment due to myopic choroidal neovascularisation (myopic CNV)2.

References:

1. Agostini H, et al. Expert Opin Biol Ther. 2025;25(7):773-787.
2. MYNZEPLI® (aflibercept) UK Summary of Product Characteristics, 2025.
3. EYLEA® (aflibercept) UK Summary of Product Characteristics.
4. European Medicines Agency (EMA). MYNZEPLI® (aflibercept) European public assessment report (EPAR). Available at: https://www.ema.europa.eu/en/d... assessment-report_en.pdf (Last accessed February 2026).
5. Cirillo S, et al. Handling and Safety of Candidate Biosimilar AVT06 Pre-Filled Syringe in Participants with Chorioretinal Vascular Disease. Presented at Maculart Meeting;Paris, France;June 29-July 1, 2025. Poster#: PH-04.
6. Alvotech. Manufacturing. Available at: https://www.alvotech.com/manuf... (Last accessed February 2026).
7. Data on file. REF-AFL-0030, 2025.
8. Alvotech. Corporate sustainability. Environmental. Available at: https://www.alvotech.com/corpo... (Last accessed February 2026).